Albendazole therapy for neurocysticercosis: A prospective double-blind trial comparing 7 versus 14 days of treatment

Neurology

Volumn 48, Issue 5, 1997, Pages 1421-1427

  Garcia, H H ^a,b,c   Gilman, R H ^a,b,c,d   Horton, J ^e   Martinez, M ^b   Herrera, G ^a   Altamirano, J ^b   Cuba, J M ^b   Rios Saavedra, N ^b   Verastegui, M ^a   Boero, J ^c   Gonzalez, A E ^c  

^a UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^b INSTITUTO NACIONAL DE CIENCIAS NEUROLÓGICAS   (Peru)

^c ASOCIACIÓN BENÉFICA PRISMA   (Peru)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; DEXAMETHASONE;

ADULT; ARTICLE; BRAIN CYSTICERCOSIS; BRAIN VENTRICLE PERITONEUM SHUNT; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INTRACRANIAL HYPERTENSION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PERU; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0030946623     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.5.1421     Document Type: Article

References (35)

1. Bryan RT. Current issues in cysticercosis: proteins, proglottides, pigs, and privies. In: Walker DH, ed. Global infectious diseases: prevention, control and eradication. Vienna: Springer-Verlag, 1992:181-203.
2. Del Brutto OH, Sotelo J. Neurocysticercosis: an update. Rev Infect Dis 1988;10:1075-1087.
3. Garcia HH, Martinez M, Gilman RH, et al. Diagnosis of cysticercosis in endemic regions. Lancet 1991;338:549-551.
4. Flisser A. Neurocysticercosis in Mexico. Parasitol Today 1988; 4:131-136.
5. Nash TE, Neva FA. Recent advances in the diagnosis and treatment of cerebral cysticercosis. N Engl J Med 1984;311: 1492-1496.
6. Garcia HH, Gilman R, Martinez M, et al. Cysticercosis as a major cause of epilepsy in Peru. Lancet 1993;341:197-200.
7. Robles-Castillo C. Tratamiento médico de la cisticercosis cerebral. Salud Publica Mex 1981;23:443-450.
8. De Ghetaldi LD, Norman RM, Douville AW. Cerebral cysticercosis treated biphasically with dexamethasone and praziquantel. Ann Intern Med 1983;99:179-181.
9. Sotelo J, Escobedo F, Rodriguez-Carbajal J, Torres B, Rubio-Donnadieu F. Therapy of parenchymal brain cysticercosis with praziquantel. N Engl J Med 1984;310:1001-1007.
10. Sotelo J, Torres B, Rubio-Donnadieu F, Escobedo F, Rodriguez-Carbajal J. Praziquantel in the treatment of neurocysticercosis: long-term follow up. Neurology 1985;35:752-755.
11. Joubert J, Jenni WK. Treatment of neurocysticercosis. S Afr Med J 1990;77:27-30.
12. Escobedo F, Penagos P, Rodriguez J, Sotelo J. Albendazole therapy for cysticercosis. Arch Intern Med 1987;147:738-741.
13. Sotelo J, Escobedo F, Penagos P. Albendazole versus praziquantel for therapy for neurocysticercosis. A controlled trial. Arch Neurol 1988;45:532-534.
14. Sotelo J, Penagos P, Escobedo F, Del Brutto OH. Short course of albendazole therapy for neurocysticercosis. Arch Neurol 1988;45:1130-1133.
15. Takayanagui OM, Jardim E. Therapy for neurocysticercosis. Comparison between albendazole and praziquantel. Arch Neurol 1992;49:290-294.
16. Cruz M, Cruz I, Horton J. Albendazole vs. praziquantel in the treatment of cerebral cysticercosis: clinical evaluation. Trans R Soc Trop Med Hyg 1991;85:244-247.
17. Botero D, Uribe CS, Sanchez JL, et al. Short course albendazole treatment for neurocysticercosis in Colombia. Trans R Soc Trop Med Hyg 1993;87:576-577.
18. Sotelo J, Del Brutto OH, Penagos P, et al. Comparison of therapeutic regimens of anticysticercal drugs for parenchymal brain cysticercosis. J Neurol 1990;237:69-72.
19. Markell EK, Voge M, John DT. Medical parasitology. 6th ed. Philadelphia: W.B. Saunders, 1986:351.
20. Diaz F, Garcia HH, Gilman RH, et al. Epidemiology of taeniasis and cysticercosis in a Peruvian village. Am J Epidemiol 1992;135:875-882.
21. Pearson RD, Hewlett EL. Niclosamide therapy for tapeworm infections. Ann Intern Med 1985;102:550-551.
22. Niedermeyer E. Epileptic seizure disorders. In: Niedermeyer E. Lopes da Silva F. eds. Electroencephalography. Baltimore: Urban & Schwarzenberg. 1982:339-428.
23. Del Brutto OH, Santibañez R, Noboa CA, Aguirre R, Diaz E, Alarcon TA. Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology 1992;42:389-392.
24. Commission on Tropical Diseases, ILAE. Relationship between epilepsy and tropical diseases. Epilepsia 1994;35:89-93.
25. Schantz PM, Moore AC. Munoz JL, et al. Neurocysticercosis in an orthodox Jewish community in New York City. N Engl J Med 1992;327:692-695.
26. Shandera WX, White AC, Chen JC, Diaz P, Armstrong R. Neurocysticercosis in Houston, Texas. Medicine (Baltimore) 1994;73:37-52.
27. McCormick GF, Zee CS, Heiden J. Cysticercosis cerebri. Review of 127 cases. Arch Neurol 1982;39:534-539.
28. Dixon HBF, Hargreaves WH. Cysticercosis (Taenia solium): a further ten years' clinical study, covering 284 cases. Q J Med 1944;13:107-121.
29. Girard R. Taeniasis-cysticercosis in Honduras. Trans R Soc Trop Med Hyg 1991;85:531-534.
30. Sarti E, Schantz PM, Plancarte A, et al. Epidemiological investigation of Taenia solium taeniasis and cysticercosis in a rural village of Michoacan state, Mexico. Trans R Soc Trop Med Hyg 1994;88:49-52.
31. Escobar A. The pathology of neurocysticercosis. In: Palacios E, Rodríguez-Carbajal J, Taveras JM, eds. Cysticercosis of the central nervous system. Springfield: Charles C Thomas, 1983: 27-54.
32. Vasquez ML, Jung H, Sotelo J. Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. Neurology 1987;37:1562.
33. Jung H, Hurtado M, Medina MT, Sanchez M, Sotelo J. Dexamethasone increases plasma levels of albendazole. J Neurol 1990;237:279-280.
34. Lobato R, Lamas E, Portillo J, et al. Hydrocephalus in cerebral cysticercosis. Pathogenic and therapeutic considerations. J Neurosurg 1981;55:786-793.
35. Vasquez V, Sotelo J. The course of seizures after treatment for cerebral cysticercosis. New Engl J Med 1992;327:696-702.